RxDoctor Payments Data

Daniel West

Nurse Practitioner · Cheyenne, WYNPI 1023877453

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations.

$560in general payments, 2019–2025

Across 27 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$104
  • ANI Pharmaceuticals, Inc.$63
  • Boehringer Ingelheim$62
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$52
  • Bayer$41
  • Novo Nordisk$35
  • plus $203 from 9 others

What the payments were for

  • Food & beverage$560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$560 in reported general payments places this provider in the 85th percentile of 150 nurse practitioner providers in Wyoming.

See all nurse practitioner providers in Wyoming

Medicare billing

Part B allowed, 2024
$40,177
Medicare patients
343
Services billed
419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$34,488
EntrestoSacubitril/Valsartan16$11,706
FarxigaDapagliflozin Propanediol12$8,635
XareltoRivaroxaban12$8,014
Metoprolol Succinate122$1,169
Atorvastatin Calcium97$751
Lisinopril39$298
Losartan Potassium44$287
Ezetimibe14$281
Rosuvastatin Calcium20$263
Metoprolol Tartrate30$219
Isosorbide Mononitrate ErIsosorbide Mononitrate18$191
Carvedilol38$189
Amlodipine Besylate64$184
Olmesartan Medoxomil12$133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$104$11,70616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 150 nurse practitioner providers in Wyoming.

Other nurse practitioner in Cheyenne

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →